- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02537223
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
Phase I Trial of BYL719 in Combination With Concurrent Cisplatin-based Chemoradiotherapy in Patients With Locoregionally Advanced Squamous Cell Carcinoma of Head and Neck (LA-SCCHN)
This is a phase 1 study (the first step in testing a new drug or combination, to see how safe the drug and/or combination are) of investigational agent BYL719 in patients with locally advanced head and neck cancer (LA-SCCHN) in combination with standard radiation and chemotherapy (cisplatin).
BYL719 is a new drug that is able to bind (attach to) and block a protein called PI3K-alpha. PI3K-alpha is part of an important pathway called EGFR/PI3K/Akt. A pathway is a series of chemical reactions among proteins in the cells that are involved in the support of normal cellular function. If the pathway is too active, due to changes in those proteins, the pathway can lead to tumor cell growth, survival and invasion. BYL719 has been shown to stop cancers in laboratory and animal studies.
This study is the first time BYL719 will be combined with radiation and chemotherapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Participants will be screened for eligibility within 30 days of the intended start of the study treatment. Procedures for research purposes done during screening include archival tumor tissue collection for pharmacodynamic and predictive biomarker research and optional HPV status (if not already known).
Eligible participants will take BYL719, by mouth, once a day, starting one week prior to start of radiation and chemotherapy, for 8 weeks. The starting dose of BYL719 is 200 mg. Participants will be asked to record their doses on a study drug diary. Participants will also receive radiation therapy every day from Monday to Friday for 7 weeks.
Chemotherapy (cisplatin) will be given intravenously on Monday of weeks 1, 4, and 7 (48 hour window during weeks 4 and 7).
While receiving the study treatment, participants will have tests and procedures done once every week for safety purposes.
After the end of the study treatment, participants will be asked to visit the centre every 2 weeks up to week 8 for additional tests and procedures for safety purposes. Between week 8-12 after completing the study treatment, participants will have tumor measurements done to assess efficacy.
Participants will continued to be followed every 3 months up to 1 year, then every 6 months for 2 years (total of 3 years).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M3G 2M9
- Princess Margaret Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to comply with study requirements
- Age >= 18 years
- Life expectancy >6 months
- Previously untreated locally advanced squamous cell carcinoma of the head and neck eligible for cisplatin-based chemoradiation
- Not have received prior anti-neoplastic treatment within 2 years
- Resolved toxicities to Grade 1 or less
- Performance status of 0-1
- Adequate organ function
- Able to swallow and retain oral medication
Exclusion Criteria:
- Enrolled on another intervention clinical trial or in prior study within 30 days.
- Taking drugs with risk of prolonging the QT interval or of causing Torsades de Pointes
- Any condition that could increase the risk to the patient by participating which may include:
- Lung disease or uncontrolled hypertension
- Cardiovascular/vascular/cardiac disease
- Uncontrolled severe infection
- Impaired lung function
- Chronic treatment with corticosteroids/immunosuppressive agents
- Not recovered from previous toxicities
- Systemic therapy within 4 weeks of the start of the study treatment
- Active bacterial, fungal or viral infection
- Significant bleeding disorders
- Uncontrolled medical disorder or active infection
- Dementia or significantly altered mental status
- Diabetes mellitus requiring insulin treatment
- Another malignancy within 2 years of the start of the study treatment
- Received live attenuated vaccines within 1 week of the start of the study treatment
- Receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzymes CYP34A or CYP2C8
- Have impaired gastrointestinal (GI) function or GI disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BYL719, Cisplatin, and Radiation Therapy
BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks.
Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses.
Radiation therapy, Monday to Friday, for 7 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Treatment Emergent Side Effects
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time from date of enrollment to date of relapse disease
Time Frame: 3 years
|
3 years
|
Number of patients who do not have locoregional relapse of disease
Time Frame: 6 months
|
6 months
|
Number of patients who do not have locoregional relapse of disease
Time Frame: 12 months
|
12 months
|
Number of patients who do not have a distant metastatic relapse of disease
Time Frame: 6 months
|
6 months
|
Number of patients who do not have a distant metastatic relapse of disease
Time Frame: 12 months
|
12 months
|
Time from date of enrolment to date of death
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Aaron Hansen, M.D., Princess Margaret Cancer Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCX-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of Head and Neck
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
University of PittsburghNational Cancer Institute (NCI)TerminatedSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and NeckUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and NeckUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Arnaud Bewley, MDNational Cancer Institute (NCI); Genentech, Inc.TerminatedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckUnited States
-
James J LeeAVEO Pharmaceuticals, Inc.CompletedSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and NeckUnited States
Clinical Trials on BYL719
-
Columbia UniversityCompleted
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsAvailablePIK3CA-Related Overgrowth Spectrum (PROS)
-
Lawson Health Research InstituteActive, not recruitingHead and Neck Squamous Cell CancerCanada
-
Peter MacCallum Cancer Centre, AustraliaNovartis PharmaceuticalsCompletedMetastatic Breast CancerAustralia
-
Yonsei UniversityUnknownRecurrent or Metastatic Squamous Cell Carcinoma of Head and NeckKorea, Republic of
-
Novartis PharmaceuticalsActive, not recruitingPIK3CA-related Overgrowth Spectrum (PROS)Spain, France, Ireland, United States
-
New Mexico Cancer Care AllianceNo longer available
-
Novartis PharmaceuticalsCompletedRelapsed and Refractory Multiple MyelomaItaly, Germany, Singapore, Australia, United States
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom